Brilinta

Brilinta(Ticagrelor) is associated with Lower Hospital Readmission Rates for Myocardial Infarction Patients at Good Samaritan Hospital based on Real World Evidence Study of Medicare Claims Data

By: Sara Riascos Apr. 12, 2022

Myocardial Infarction is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payers such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Brilinta(Ticagrelor) is an oral antiplatelet prescribed by doctors to reduce the risk of having, or dying from a heart attack or stroke. Studies have shown that the use of Brilinta(Ticagrelor) reduces the risk of death from vascular causes, myocardial infarctions, and strokes. Brilinta is also approved in more than 110 countries to prevent atherothrombotic events after a myocardial infarction.

Brilinta (Ticagrelor) is associated with Lower Hospital Readmission Rates for Myocardial Infarction Patients at Vassar Brothers Medical Center based on Real World Evidence Study of Medicare Claims Data

By: Sara Riascos Mar. 25, 2022

Myocardial Infarction is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payors such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Brilinta (Ticagrelor) is an oral antiplatelet prescribed by doctors to reduce the risk of having, or dying from a heart attack or stroke. Studies have shown that the use of Brilinta (Ticagrelor) reduces the risk of death from vascular causes, myocardial infarctions, and strokes. Brilinta is also approved in more than 110 countries to prevent atherothrombotic events after a myocardial infarction.

Brilinta (Ticagrelor) is associated with Lower Hospital Readmission Rates for Myocardial Infarction Patients at St Francis Hospital - The Heart Center based on Real World Evidence Study of Medicare Claims Data

By: Sara Riascos Mar. 24, 2022

Myocardial Infarction is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payors such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Brilinta (Ticagrelor) is an oral antiplatelet prescribed by doctors to reduce the risk of having, or dying from a heart attack or stroke. Studies have shown that the use of Brilinta (Ticagrelor) reduces the risk of death from vascular causes, myocardial infarctions, and strokes. Brilinta is also approved in more than 110 countries to prevent atherothrombotic events after a myocardial infarction.